Press Releases


Aladdin Healthcare Technologies SE announces it has co-published a scientific paper on AI to target ageing

(BERLIN, Germany and LONDON, England) 12 December 2019 - Aladdin Healthcare Technologies SE (“Aladdin”), a leading developer of next generation breakthroughs in age-related disease accelerated by the integration of leading science and AI today announced it has co-published a scientific paper, in the ‘Mechanisms of Ageing and Development’ journal within Science Direct by Elsevier.

The paper titled, ‘The NAD+-mitophagy axis in healthy longevity and in artificial intelligence-based clinical applications’, delves into the concept that NAD+ could hold the key to early diagnosis and delay of neurodegenerative diseases. The paper focuses on 3 key points:

  • Summarizing the importance of NAD+ and mitophagy in healthy longevity.
  • Proposing an NAD+-mitophagy axis in health and disease, especially in neurodegenerative diseases.
  • Discuss the importance and how to use artificial intelligence (AI) in the NAD+-mitophagy axis-based mechanistic studies, drug development.

Advances in our understanding of the molecular and cellular roles of NAD+ in mitophagy will lead to novel approaches for facilitating healthy mitochondrial homoeostasis that could serve as a promising therapeutic strategy to counter ageing-associated pathologies and/or accelerated ageing.

The paper shows that by collaborating with academic and medical partners Aladdin is changing the approach to early diagnosis of age-related disease using our strong AI capability. This forms the foundation for innovation into new products within this market.

Please follow this link to access the full paper:

Wade Menpes-Smith (Chairman)

End of Media Release